Evolent Health
EVH
240 hedge funds and large institutions have $1.38B invested in Evolent Health in 2024 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 90 increasing their positions, 70 reducing their positions, and 70 closing their positions.
58% more call options, than puts
Call options by funds: $20.2M | Put options by funds: $12.8M
29% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 70
6.33% less ownership
Funds ownership: 111.37% → 105.03% (-6.3%)
8% less funds holding
Funds holding: 262 → 240 (-22)
19% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 70
62% less capital invested
Capital invested by funds: $3.66B → $1.38B (-$2.28B)
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Top Buyers
| 1 |
CCM
Cadian Capital Management
New York
|
+$91.8M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$45.7M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$28.8M |
| 4 |
EC
Engaged Capital
Newport Beach,
California
|
+$24.9M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
+$20.6M |
Top Sellers
EVH Hedge Fund Activity: Q4 2024 in Review
240 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q4 2024, worth a combined $1.38B — down 62% from $3.66B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of EVH and 57 opened new positions — a net loss of 13 holders — while 70 trimmed existing stakes and 90 added.
The largest buyer was Cadian Capital Management, opening a new position worth an estimated $91.8M. The largest seller was RA Capital Management, cutting an estimated $86.8M.
- 240 institutional investors held Evolent Health (EVH) as of Q4 2024, down from 262 in Q3 2024.
- Funds reported $1.38B of Evolent Health stock for Q4 2024, down 62% quarter-over-quarter.
- 57 funds opened new Evolent Health positions in Q4 2024 and 70 closed out, a net change of -13 holders.
- The largest Evolent Health buyer in Q4 2024 was Cadian Capital Management, an estimated $91.8M added.
- The largest Evolent Health seller in Q4 2024 was RA Capital Management, an estimated $86.8M sold.
Based on aggregated 13F filings for Q4 2024.